10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Ionis Pharmaceuticals rallied 4% pre-market today, after is announced a new collaboration to develop IONIS-FB-LRx for the treatment of complement-mediated diseases, which could earn the company nearly $760 million. 10 October 2018
At the upcoming congress of the European Society for Medical Oncology (ESMO), Eli Lilly will present a range of new data, including on the investigational compound pegilodecakin. 10 October 2018
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Crysvita (burosumab) within its marketing authorization, for treating X-linked hypophosphatemia (XLH) in children and young people with growing bones in England and Wales. 10 October 2018
New data showing treatment with a single intravenous (IV) dose of Stelara (ustekinumab) induces clinical remission and response in adults with moderate to severe ulcerative colitis (UC) who previously experienced an inadequate response or were intolerant to conventional or biologic therapies are being presented today at the American College of Gastroenterology (ACG) Scientific Meeting 2018. 9 October 2018
Swiss rare diseases focused biotech Therachon today announced the acquisition of Canada-based GLyPharma Therapeutic for an undisclosed amount. 9 October 2018
Results from the Phase III STYLE study show that Otezla (apremilast) 30mg twice daily achieved a highly statistically-significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA) response [defined as ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline] at week 16 compared with placebo. 9 October 2018
Dublin-headquartered Californian firm Theravance Biopharma has announced positive new data from multiple studies of Vibativ (telavancin) at IDWeek 2018. 8 October 2018
Shares of US biotech firm Akcea Therapeutics gained 4.39% to $31.85 by close of trading and a further 2.04% to $32.50 in after-hours on Friday, after the company revealed that the US Food and Drug Administration had approved Tegsedi (inotersen) for the treatment of the polyneuropathy of hereditary transthyretin (hATTR) amyloidosis in adults. 8 October 2018
Sitryx, a new, Oxford, UK-based biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces it has closed its Series A financing round. 8 October 2018
A month after the UK's National Health Service (NHS) agreed a deal to make Novartis’ Kymriah (axicabtagene ciloleucel) available to children and young people with a rare form of leukemia, a deal has been announced to bring another CAR-T therapy to English patients. 5 October 2018
US biotech bluebird bio has had its marketing authorization application accepted by the European Medicines Agency for its investigational LentiGlobin gene therapy for treatment of adults and adolescents with transfusion-dependent β-thalassemia (TDT) and a non-β0/β0 genotype. 5 October 2018
There was good news for Roche with the coveted wider indication for its hemophilia drug in the USA, so increasing its focus on diseases beyond cancer to help replace revenue from older products that have, or will soon, lost patent exclusivity. 5 October 2018
Belgian clinical-stage biotech firm Celyad has entered into an exclusive agreement with the UK’s Horizon Discovery for the use of its shRNA technology to generate Celyad’s second non-gene-edited allogeneic platform. 5 October 2018
Arrowhead Pharmaceuticals saw its shares surge 19% to a high of $20.31 pre-market but plunge 15.7% to $16.04 by late morning New York trading, despite announcing a licensing deal that could earn it as much as $3.7 billion. 4 October 2018
UK-based biotech firm Orchard Therapeutics has been awarded the fast track PRIME Designation from the European regulator for its investigational gene therapy OTL-300. 4 October 2018
OxStem, an Oxford University spin-out developing regenerative medicine-based therapies, is launching two subsidiary companies to develop regenerative treatments for diabetes and chronic inflammation and wound healing. 4 October 2018
In a second major deal signed this year, biotech firm HiFiBiO Therapeutics has entered into a research collaboration and license agreement with Gilead Sciences company Kite, to develop technology supporting the discovery of neoantigen-reactive T cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors. 4 October 2018
The Australian government has announced that it will make a drug for severe inflammatory spinal arthritis more affordable when it is listed on the Pharmaceutical Benefits Scheme (PBS), saving patients more than A$15,000 ($10,870) a year. 4 October 2018